02/20/2026
PrE0510 is a randomized phase 2 clinical trial exploring the optimal dose of ivonescimab with carboplatin and etoposide in extensive-stage small cell lung cancer ( ). For more information: https://clinicaltrials.gov/study/NCT07057791
Innovative cancer research studies developed through industry partnerships and networks.
1818 Market Street, Suite 3000
Philadelphia, PA
19118
| Monday | 9am - 5pm |
| Tuesday | 9am - 5pm |
| Wednesday | 9am - 5pm |
| Thursday | 9am - 5pm |
| Friday | 9am - 5pm |
Be the first to know and let us send you an email when PrECOG Cancer Research Group posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
PrECOG, LLC develops and leads research that provides new hope for patients and their families. This is accomplished through innovation, working with oncology research leaders, partnerships with research groups, and collaborations with industry partners. Our goal is to design, implement, and publish results for clinical trials that support the ever-evolving needs of patients with cancer and our underlying knowledge of cancer diseases.